A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

Phase 2 Completed NCT05071664

Condition	Arthritis, Psoriatic
Phase	Phase 2
Sponsor	Janssen Research & Development, LLC
Status	Completed
Enrollment	91 participants
Interventions	Guselkumab, Golimumab
Start date	Oct 25, 2021
Completion date	May 14, 2024
Results posted	Jul 23, 2026

Summary

The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapies by assessing clinical response compared with guselkumab monotherapy.

Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 24

Week 24 · Percentage of participants

Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w	28.8 Percentage of participants
Group 2: Guselkumab 100 mg q4w Plus Placebo	21.9 Percentage of participants

p-value	=0.557
Odds Ratio (OR)	1.4 (95% CI 0.6–3.3)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With A — UCB Biopharma SRL
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis — AbbVie

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский